This topic contains a solution. Click here to go to the answer

Author Question: Which describes recommended criteria for use of enteral feedings in a pediatric patient? a. Weight ... (Read 61 times)

V@ndy87

  • Hero Member
  • *****
  • Posts: 571
Which describes recommended criteria for use of enteral feedings in a pediatric patient?
 a. Weight loss of 5 pounds in 6 months
 b. Unable to obtain 20 of caloric needs by mouth
  c. Requiring over 4 hours a day to eat
 d. Inadequate oral intake for over 48 hours
 e. Persistent TSF below the 50th percentile

Question 2

The most common clinical sign of fatty liver is _______________.
 Fill in the blank(s) with correct word



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

mcinincha279

  • Sr. Member
  • ****
  • Posts: 316
Answer to Question 1

c

Answer to Question 2

hepatomegaly




V@ndy87

  • Member
  • Posts: 571
Reply 2 on: Aug 20, 2018
YES! Correct, THANKS for helping me on my review


essyface1

  • Member
  • Posts: 347
Reply 3 on: Yesterday
Excellent

 

Did you know?

Children of people with alcoholism are more inclined to drink alcohol or use hard drugs. In fact, they are 400 times more likely to use hard drugs than those who do not have a family history of alcohol addiction.

Did you know?

Fatal fungal infections may be able to resist newer antifungal drugs. Globally, fungal infections are often fatal due to the lack of access to multiple antifungals, which may be required to be utilized in combination. Single antifungals may not be enough to stop a fungal infection from causing the death of a patient.

Did you know?

In 2010, opiate painkllers, such as morphine, OxyContin®, and Vicodin®, were tied to almost 60% of drug overdose deaths.

Did you know?

Most fungi that pathogenically affect humans live in soil. If a person is not healthy, has an open wound, or is immunocompromised, a fungal infection can be very aggressive.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library